If this is not your name, click here.
| | If this is not your name, click here. | | |
| | Contact Us | Order Now | Journals | Bookstore | Register a colleague | | |
| |  AACR: Paclitaxel Carboplatin Combination Therapy Might Be as Effective as Mitoxantrone Alone for Patients With Hormone-Refractory Prostate Cancer By Jerry Ingram ORLANDO, FL -- April 1, 2004 -- Preliminary results of a phase 2 study suggest that a paclitaxel plus carboplatin combination may be as effective as mitoxantrone alone for patients with hormone refractory prostate cancer, researchers reported in a poster session here at the American Association for Cancer Research 95th Annual Meeting. "The major finding of our study is that hormone resistant prostate cancer must not be considered any more as chemoresistant," said presenter Philippe Chollet, MD, Centre Jean Perrin, Clermont-Ferrand, France. "Taxol carboplatin is a good and effective combination as mitoxantrone alone is. In addition, prostate cancer must be treated in the same way as breast cancer." Dr. Chollet and his team conducted their study to compare the efficiency and toxicity of paclitaxel-carboplatin with mitoxantrone alone for treatment of patients with hormone-refractory prostate cancer. They randomised 17 patients to paclitaxel 175 mg/m2 plus IV carboplatin at an area-under-the-curve (AUC) of 5 on day 1 of every 3-week cycle or IV mitoxantrone 12 mg/m2 on day 1 of every 3-week cycle. All patients received ongoing hormonal therapy. Investigators assessed prostate specific antigen (PSA) levels every cycle and also conducted clinical evaluations every 3 cycles. Treatment was continued until disease progression or excessive toxicity. Among the 8 patients who received paclitaxel-carboplatin for a median of 3 courses, 5 were able to be evaluated. The 3 patients dropped out of the study due to either allergy or death. Two patients had a PSA decrease greater than 50%. One of these patients experiencing a complete response and stability of bone metastasis, the other showed improvement in terms of bone metastases. One patient had stabilised PSA levels and disease, and bone metastases improved. However, 2 patients had disease progression. Two patients developed grade 1 and grade 3 peripheral neuropathy after cycle 9, 1 developed paclitaxel allergy, 1 thrombocytopaenia grade 1, 2 grade 1 and grade 2 anaemia, and 1 septic shock that resulted in death. Dr. Chollet said that these results, although preliminary, suggest that combination of paclitaxel and carboplatin might be more effective than mitoxantrone for patients with hormone refractory prostate cancer. Studies are ongoing and more research is needed to determine if there is any influence of this combination on survival, he added.
[Study title: Phase II Study of Paclitaxel Carboplatin Combination Versus Mitoxantrone in Patients With Hormone-Refractory Prostate Cancer: Preliminary Results. Abstract 4483]
|
